Matches in SemOpenAlex for { <https://semopenalex.org/work/W3166196440> ?p ?o ?g. }
- W3166196440 endingPage "3821" @default.
- W3166196440 startingPage "3806" @default.
- W3166196440 abstract "Overcoming acquired drug resistance is a primary challenge in cancer treatment. Notably, more than 50% of patients with BRAFV600E cutaneous metastatic melanoma (CMM) eventually develop resistance to BRAF inhibitors. Resistant cells undergo metabolic reprogramming that profoundly influences therapeutic response and promotes tumor progression. Uncovering metabolic vulnerabilities could help suppress CMM tumor growth and overcome drug resistance. Here we identified a drug, HA344, that concomitantly targets two distinct metabolic hubs in cancer cells. HA344 inhibited the final and rate-limiting step of glycolysis through its covalent binding to the pyruvate kinase M2 (PKM2) enzyme, and it concurrently blocked the activity of inosine monophosphate dehydrogenase, the rate-limiting enzyme of de novo guanylate synthesis. As a consequence, HA344 efficiently targeted vemurafenib-sensitive and vemurafenib-resistant CMM cells and impaired CMM xenograft tumor growth in mice. In addition, HA344 acted synergistically with BRAF inhibitors on CMM cell lines in vitro. Thus, the mechanism of action of HA344 provides potential therapeutic avenues for patients with CMM and a broad range of different cancers. SIGNIFICANCE: Glycolytic and purine synthesis pathways are often deregulated in therapy-resistant tumors and can be targeted by the covalent inhibitor described in this study, suggesting its broad application for overcoming resistance in cancer." @default.
- W3166196440 created "2021-06-22" @default.
- W3166196440 creator A5004100578 @default.
- W3166196440 creator A5007084558 @default.
- W3166196440 creator A5011959227 @default.
- W3166196440 creator A5018849034 @default.
- W3166196440 creator A5023603241 @default.
- W3166196440 creator A5026897749 @default.
- W3166196440 creator A5034528977 @default.
- W3166196440 creator A5039959145 @default.
- W3166196440 creator A5040451497 @default.
- W3166196440 creator A5044460005 @default.
- W3166196440 creator A5049144741 @default.
- W3166196440 creator A5051365781 @default.
- W3166196440 creator A5052106976 @default.
- W3166196440 creator A5054373904 @default.
- W3166196440 creator A5056713429 @default.
- W3166196440 creator A5067257752 @default.
- W3166196440 creator A5070325485 @default.
- W3166196440 creator A5070431556 @default.
- W3166196440 creator A5073799458 @default.
- W3166196440 creator A5074757293 @default.
- W3166196440 creator A5080661528 @default.
- W3166196440 creator A5085216597 @default.
- W3166196440 creator A5088341425 @default.
- W3166196440 date "2021-06-07" @default.
- W3166196440 modified "2023-10-11" @default.
- W3166196440 title "Dual Covalent Inhibition of PKM and IMPDH Targets Metabolism in Cutaneous Metastatic Melanoma" @default.
- W3166196440 cites W1498612297 @default.
- W3166196440 cites W1515331240 @default.
- W3166196440 cites W1541248931 @default.
- W3166196440 cites W1950829641 @default.
- W3166196440 cites W1975215468 @default.
- W3166196440 cites W1980121152 @default.
- W3166196440 cites W1981966610 @default.
- W3166196440 cites W1982789056 @default.
- W3166196440 cites W1992578437 @default.
- W3166196440 cites W1995050941 @default.
- W3166196440 cites W2010993054 @default.
- W3166196440 cites W2015207840 @default.
- W3166196440 cites W2016956375 @default.
- W3166196440 cites W2017746705 @default.
- W3166196440 cites W2031134972 @default.
- W3166196440 cites W2033240778 @default.
- W3166196440 cites W2036160927 @default.
- W3166196440 cites W2072451938 @default.
- W3166196440 cites W2074005278 @default.
- W3166196440 cites W2103147617 @default.
- W3166196440 cites W2106204137 @default.
- W3166196440 cites W2106543129 @default.
- W3166196440 cites W2113988246 @default.
- W3166196440 cites W2116201681 @default.
- W3166196440 cites W2117692326 @default.
- W3166196440 cites W2120404934 @default.
- W3166196440 cites W2125836344 @default.
- W3166196440 cites W2128123076 @default.
- W3166196440 cites W2131040858 @default.
- W3166196440 cites W2134471382 @default.
- W3166196440 cites W2136474966 @default.
- W3166196440 cites W2142748510 @default.
- W3166196440 cites W2161471210 @default.
- W3166196440 cites W2195075045 @default.
- W3166196440 cites W2234115940 @default.
- W3166196440 cites W2283432584 @default.
- W3166196440 cites W2342564029 @default.
- W3166196440 cites W2395626624 @default.
- W3166196440 cites W2410510133 @default.
- W3166196440 cites W2430132928 @default.
- W3166196440 cites W2553644640 @default.
- W3166196440 cites W2577444357 @default.
- W3166196440 cites W2592487518 @default.
- W3166196440 cites W2604376168 @default.
- W3166196440 cites W2619021353 @default.
- W3166196440 cites W2622009965 @default.
- W3166196440 cites W2622185466 @default.
- W3166196440 cites W2705421977 @default.
- W3166196440 cites W2765597781 @default.
- W3166196440 cites W2767190680 @default.
- W3166196440 cites W2783904016 @default.
- W3166196440 cites W2785187242 @default.
- W3166196440 cites W2789976681 @default.
- W3166196440 cites W2792782033 @default.
- W3166196440 cites W2810661705 @default.
- W3166196440 cites W2810902531 @default.
- W3166196440 cites W2891587993 @default.
- W3166196440 cites W2893106133 @default.
- W3166196440 cites W2901942542 @default.
- W3166196440 cites W2911915561 @default.
- W3166196440 cites W2945731602 @default.
- W3166196440 cites W2982321167 @default.
- W3166196440 cites W2992153811 @default.
- W3166196440 cites W4232574319 @default.
- W3166196440 doi "https://doi.org/10.1158/0008-5472.can-20-2114" @default.
- W3166196440 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34099492" @default.
- W3166196440 hasPublicationYear "2021" @default.
- W3166196440 type Work @default.
- W3166196440 sameAs 3166196440 @default.
- W3166196440 citedByCount "8" @default.